logo
Gold prospector 'scared' by crumbling five-metre discovery in Aussie bush

Gold prospector 'scared' by crumbling five-metre discovery in Aussie bush

Yahoo3 days ago
Deep in the bush are the ruins of pits that once contained one of the 19th Century's most dangerous and commonly used chemicals, cyanide. The pits were used to extract gold from ore, and their locations can prove valuable for modern-day prospectors searching for long-lost nuggets. Others search for ruined huts, abandoned mines and even old maps.
Dusty, who quit her job to search for gold full-time, recently photographed several five-metre-wide pits outside the central Victorian town of Moliagul. 'I never knew it was there. I was just climbing up the hill and realised I was standing on top of the tank, it's wild to have this hidden history,' she told Yahoo News Australia, after reporting the find on her social media page.
Back in the day, the pits were drained directly into the bush, and this could contaminate fresh water, killing off fish, wildlife and even people. Death in humans can occur within minutes of cyanide poisoning, and within seconds, exposure can cause headache, loss of consciousness, nausea, and difficulty breathing.
Related: ⛏️ Gold prospector's incredible find in 'remote' Aussie bush
Historical pictures show men standing on top of the pits at great risk to their own safety.
'When I come across them in the bush, I stand roughly where they would have been working, and I think one slip and they would have been in the tank, and they would have been dead,' Dusty said.
'I just don't know how people could have walked along with their big wooden paddles and stirred the cyanide slurry and thought nothing of it. It scares me even now, and it always blows me away when I find them.'
Today, undisturbed pits pose little danger to walkers, according to Heritage Victoria, which manages several of the historic sites around the goldfields region.
Although there are alternatives, cyanide continues to be used for gold extraction around the world. Even though the methods have been modernised, and the risks of contamination are low, University of Western Sydney water expert, Associate Professor Ian Wright, is concerned about the practice.
'There are different forms of cyanide, and there are lots that have long-term impacts,' he told Yahoo News.
🥺 Emotional decision looms as ancient graveyard faces one in 100 year storm prediction
🌵 Remarkable 26-year change revealed on Aussie desert property
☔️ Weather event sees Aussie town overrun by 'rarely observed' phenomenon
Twenty-five years ago in Romania, a joint venture between the country's government and Australian company Esmeralda Exploration resulted in 100,000 cubic metres of water contaminated with cyanide leaking into the Somes River and then into the Danube. Foxes, otters and birds all died after eating contaminated fish, and the problem spread to neighbouring Serbia and Hungary.
Last year, elevated levels of cyanide were detected around Victoria Gold's Eagle gold mine in Canada's Yukon Territory following the discharge of millions of litres of water laced with the chemical. The leak resulted in the company being placed in receivership and its stock being delisted.
'In most mine operations, they do things well. But the tragedy for something like cyanide, even if leaks are super rare, is that the consequences can be absolutely terrible,' Wright said.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New weekly injection for Parkinson's could replace daily pill for millions, study suggests
New weekly injection for Parkinson's could replace daily pill for millions, study suggests

Fox News

time10 hours ago

  • Fox News

New weekly injection for Parkinson's could replace daily pill for millions, study suggests

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for daily pills. Scientists from the University of South Australia (UniSA) developed a long-acting injectable formulation that provides two key Parkinson's medications for an entire week. There is currently no cure for Parkinson's, which is the second-most common neurological disorder, affecting more than one million Americans, according to the Parkinson's Foundation. To manage symptoms like tremors, rigidity and slow movement, patients typically take daily oral medications, such as levodopa and carbidopa, according to the university's press release. This method can be especially difficult for individuals who have trouble swallowing or are otherwise unable to take the pills consistently, leading to irregular medication levels, increased side effects and reduced effectiveness. Levodopa is the "gold-standard therapy for Parkinson's," according to lead researcher Professor Sanjay Garg at UniSA, but its short lifespan means it must be taken several times a day. The researchers tested an injectable gel implant that combines an FDA-approved biodegradable substance with a pH-sensitive substance to achieve a controlled and sustained drug release. The gel is injected through a single shot under the skin or into the muscle tissue, which means there's no need for a surgical implant and discomfort is minimal, they noted. The team found that the gel gradually released the key Parkinson's medications (90% of the levodopa drug and 81% of the carbidopa) over the course of one week. The findings were published in the journal Drug Delivery and Translational Research. "Reducing the frequency of dosing from multiple times a day to a weekly injection is a major step forward in Parkinson's therapy," Garg said in the release. "We're not just improving how the drug is delivered; we're improving patients' lives." Extensive lab tests confirmed the system's effectiveness and safety. "We're not just improving how the drug is delivered; we're improving patients' lives." The implant degraded by over 80% within a week and showed no significant toxicity in cell viability tests. "The implications of this research are profound," Garg added. Deepa Nakmode, a PhD student at the University of South Australia, noted that this method is designed to release both levodopa and carbidopa steadily over one week, maintaining consistent plasma levels and reducing the risks associated with fluctuating drug concentrations. "After years of focused research, it's incredibly rewarding to see our innovation in long-acting injectables for Parkinson's disease reach this stage," he said in the release. The team's invention has now been filed for an Australian patent, Nakmode added. The technology could also be adapted for other chronic conditions, such as cancer, diabetes, neurodegenerative disorders, chronic pain and infections that require long-term drug delivery, according to Garg. The system can be tuned to release drugs over a period ranging from a few days to several weeks, depending on therapeutic needs. For more Health articles, visit Scientists hope to start clinical trials in the near future and are exploring opportunities to make the gel commercially available.

New Core Outcomes May Transform Stillbirth Care
New Core Outcomes May Transform Stillbirth Care

Medscape

time13 hours ago

  • Medscape

New Core Outcomes May Transform Stillbirth Care

TOPLINE: A new core outcome set for stillbirth care developed with the input from international stakeholders can be used in future trials and systematic reviews to reduce outcome-reporting bias, facilitate comparisons of interventions in meta-analyses, and ultimately reduce research wastage. METHODOLOGY: Researchers conducted an international consensus study using data from the modified Delphi method and consensus meetings to develop a core outcome set to guide future stillbirth care research. The core outcome set was developed following the methodological consensus standards outlined by the Core Outcome Measures in Effectiveness Trials initiative standards and supported by the relevant published literature. Researchers invited 542 stakeholders, including 381 parents or family members who had experienced stillbirth and 192 healthcare professionals or researchers (31 of whom identified as both a parent and a professional), from 29 countries across Africa, Australia, Europe, North America, South America, and Asia. Participants completed two rounds of Delphi surveys using Research Electronic Data Capture, followed by four consensus meetings to determine the final core outcome set. TAKEAWAY: Core outcomes for all stillbirth care studies were life-threatening complications, maternal death, parents' experience of respectful and supportive care, grief, mental health and emotional well-being, isolation, stigma, impact on work, and impact on family relationships. For studies investigating the cause of stillbirth, researchers identified two additional core outcomes: identification of the cause of death and parents' understanding of that cause. Studies assessing subsequent pregnancy care should measure outcomes such as antenatal complications for the mother and baby, baby survival, neonatal outcomes, and attachment to the baby. Studies focusing on stillbirth associated with a multiple pregnancy should consider outcomes such as survival of other babies, preterm birth, pregnancy complications for the baby, and neonatal outcomes. IN PRACTICE: "The development of a minimum agreed set of outcomes represents a significant milestone to address inconsistent outcome collection and reporting in studies of care after stillbirth," the authors wrote. SOURCE: This study was led by Danya Bakhbakhi, Translational Health Sciences, University of Bristol, Bristol, England. It was published online on July 07, 2025, in BJOG: An International Journal of Obstetrics & Gynaecology. LIMITATIONS: Overall, 69.8% of participating parents had university or college education, which is higher than the population average, potentially affecting the generalisability of the core outcome set. The majority of stakeholders were from high-income countries. This study did not include stakeholders who did not speak English. DISCLOSURES: This study received support from the National Institute for Health and Care Research through a doctoral fellowship. Two authors reported receiving grant funding for stillbirth research. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store